

Drugs and Therapeutics Advisory Board Meeting

Thursday, October 21, 2021 8:30am-11am

Agenda

- I. Call to Order
- II. Roll Call
- III. Welcome
- IV. Agenda and Conflict of Interest Review
- V. Approval of the Minutes
- VI. Public Comments
- VII. Rybelsus Clarification
- VIII. PDL Drug Appeals
 - a. None at this meeting
- IX. New Drug Appeals
 - a. None at this meeting
- X. Drug Class Review- Ryan Rodriguez, PharmD Clinical review (with discussion and vote)
 - a. Growth Hormone
 - b. Multiple Sclerosis-oral
 - c. Multiple Sclerosis-injectable
- XI. New Drug Initial Review-Ryan Rodriguez, PharmD (with discussion and vote)
 - a. Qelbree
 - b. Verquvo
- XII. Future Agenda Preview -Sheri Dolan
- XIII. Provider Requested Reviews-Sheri Dolan
- XIV. Department Update-Jose Jimenez
- XV. Adjournment

Registered Speakers

Speaker	Product	Organization
Brooke Wilkins, PharmD	Kesimpta	Novartis
Karen Malamut, DO	Verquvo	Merck
Vignesh Shettar, MD	Rybelsus	Macneal Endocrinology
Opeoluwa Fagbemi, Senior Regional Medical Manager	Qelbree	Supernus
Rick Szymialis, Field HEOR Director	Zeposia	Bristol Myers Squibb